News and Media
News and Media
Valerio Therapeutics announces a capital reduction motivated by losses by reducing the nominal value of the Company’s shares
February 6, 2024
Half-year liquidity contract statement for Valerio Therapeutics
January 25, 2024
Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities (English)
New identity unveiled, with the aim at developing innovative therapies […]
September 28, 2023
Onxeo changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023 (English)
All the resolutions approved by the Board of Directors were […]
June 6, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures (English)
May 16, 2023
Combined General Meeting of June 6, 2023: availability of preparatory documents and participation & voting procedures
May 16, 2023
Publication of the 2022 Annual Financial Report
April 28, 2023
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
April 24, 2023
Onxeo will publish its full-year results on April 24, 2023
April 21, 2023
Onxeo will publish its full-year results on April 14, 2023
March 14, 2023
Onxeo: report on the Extraordinary General Meeting of February 6, 2023
February 6, 2023
Onxeo Continues to Strengthen its Board of Directors
November 23, 2021
New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments
August 12, 2021
Press Release Signup
Subscribe to receive our Press Releases when they come out.
